Compare Expedia Group Inc (EXPE) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Tempus AI — how do they compare? Expedia Group Inc trades at $269.5 (market cap $31.07B), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Expedia Group Inc is far larger — about 2.4× Tempus AI's market cap, and Expedia Group Inc pays a 0.74% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Tempus AI for 22 Days on average.
| EXPE | TEM | |
|---|---|---|
Market Cap | $31.07B | $12.77B |
Volume | 1,305,431 | 8,980,490 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $339.13 | $99.28 |
52-Week Low | $188.51 | $41.55 |
Typical Hold Time | 48 Days | 22 Days |
Enterprise Value | $29.63B | $13.40B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $270.13, up 3.95% today, with strong earnings beats in recent quarters but facing technical bearish signals. The company shows robust fundamentals with 2025 revenue of $14.73B, net income of $1.29B, and healthy cash flow generation. Recent news highlights competitive threats from AI travel agents and workforce reductions, while analyst consensus remains mixed with a $335.06 price target.
EXPE presents a valuation opportunity with P/E of 16.28 below sector averages, but faces significant headwinds from AI disruption in travel booking. The stock's 199% ROE and consistent earnings outperformance support long-term growth potential, though near-term technical weakness and competitive pressures require careful monitoring.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
